think a frequently seen trend, and sol think we a frequently seen trend, and sol think we have to hope that this is all going think we have to hope that this is all going to be around us but not so debilitating both to human beings and two debilitating both to human beings and two economies, and that seems to be what and two economies, and that seems to be what is and two economies, and that seems to be what is happening. it is not as bad as be what is happening. it is not as bad as it was a year ago. let s be what is happening. it is not as bad as it was a year ago. let s pick u . bad as it was a year ago. let s pick u- what bad as it was a year ago. let s pick up what damien bad as it was a year ago. let s pick up what damien was bad as it was a year ago. let s pick up what damien was saying - bad as it was a year ago. let s pick up what damien was saying about | bad as it was a year ago. let s pick. up what damien was saying about the problem be it s all very well fo
Novavax submitted to WHO all modules required for the evaluation of NVX-CoV2373, its protein-based Covid-19 vaccine, days after receiving its first emergency use authorization from Indonesia
we know that india, which is the biggest producer of vaccines, the serum institute in india, india s said, look, we re going to pause any exports on covid 19 because we are battling our own massive crisis here. so where are the vaccines going to come from? that s a very good question. and if you recall, the serum institute in india was only supplying us with the astrazeneca vaccine through the covax facility. at the same time, covax was designed to support the continent with up to about 20% to 30% of our vaccine needs. we as a continent under the leadership of the african union have establish what we call the african vaccine acquisition task team that was designed to complement the efforts of covax and take us to the 60%. so in that arrangement, we have secured 220 million doses of thejohnson & johnson vaccine. so any country in africa who wants to acquire vaccines needs to go to the platform, the platform that we established at the african
and say, and recognise that maybe, and just maybe, the strategy that we had with respect to making india the sole supplier of that particular vaccine was probably not the best. we should have minimised our risk by having several places around the world that could produce that vaccine. nobody anticipated the situation in india. so you re not angry, you re not angry like strive masiyiwa. was he wrong to say that he was beyond anger, then? i think the situation is very concerning, and it s not necessarily about being angry. it is very concerning that because of the situation in india, we are not, as a continent, going to meet our vaccination needs by the end of this year, which was heavily reliant on supplies from the serum institute in india. so i m deeply concerned with that scenario. all right. so you ve talked about how you re looking at other vaccines, notjust astrazeneca, which is produced mostly in india, you ve said, and gavi, the international vaccine alliance, which is
but we have to step back and say, and recognise that maybe, and just maybe, the strategy that we had with respect to making india the sole supplier of that particular vaccine was probably not the best. we should have minimised our risk by having several places around the world that could produce that vaccine. nobody anticipated the situation in india. so you re not angry, you re not angry like strive masiyiwa. was he wrong to say that he was beyond anger, then? i think the situation is very concerning, and it s not necessarily about being angry. it is very concerning that because of the situation in india, we are not, as a continent, going to meet our vaccination needs by the end of this year, which was heavily reliant on supplies from the serum institute in india. so i m deeply concerned with that scenario. all right. so you ve talked about how you re looking at other vaccines, notjust astrazeneca, which is produced mostly in india, you ve said,